{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reyataz+Atazanavir", "query": { "intervention": "Reyataz Atazanavir" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 141, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reyataz+Atazanavir&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T07:53:31.123Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00120393", "title": "Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/ritonavir +2 NRTIs (immediate Switch Group)", "type": "DRUG" }, { "name": "LPV/r +2 NRTIs (Delayed/optional Switch Group)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2004-01", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2010-02-05", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120393" }, { "nct_id": "NCT00002240", "title": "Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-03", "completion_date": "2001-12", "has_results": false, "last_update_posted_date": "2011-05-04", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 16, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002240" }, { "nct_id": "NCT00884793", "title": "Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "Study NNRTI", "type": "DRUG" }, { "name": "Study PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2008-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-07-23", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884793" }, { "nct_id": "NCT00357604", "title": "Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)", "type": "DRUG" }, { "name": "Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 22, "start_date": "2006-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2011-04-08", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00357604" }, { "nct_id": "NCT01102972", "title": "A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Reyataz + Norvir + Truvada", "type": "DRUG" }, { "name": "Reyataz + Epzicom", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 297, "start_date": "2010-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2013-11-19", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 44, "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01102972" }, { "nct_id": "NCT01602822", "title": "Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kenneth H. Mayer, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2012-02", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01602822" }, { "nct_id": "NCT00525239", "title": "HIV Antiretroviral Drugs and Metabolism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-03", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2011-03-16", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525239" }, { "nct_id": "NCT02386098", "title": "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "BMS-955176", "type": "DRUG" }, { "name": "Atazanavir (ATV)", "type": "DRUG" }, { "name": "Ritonavir (RTV)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Tenofovir (TDF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2015-07-08", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 16, "location_summary": "Beverly Hills, California • Los Angeles, California • Palm Springs, California + 13 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02386098" }, { "nct_id": "NCT01384734", "title": "HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "BMS-663068 400 mg", "type": "DRUG" }, { "name": "BMS-663068 800 mg", "type": "DRUG" }, { "name": "BMS-663068 600 mg", "type": "DRUG" }, { "name": "BMS-663068 1200 mg", "type": "DRUG" }, { "name": "Raltegravir 400 mg", "type": "DRUG" }, { "name": "Tenofovir 300 mg", "type": "DRUG" }, { "name": "Ritonavir 100 mg", "type": "DRUG" }, { "name": "Atazanavir 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2011-07-26", "completion_date": "2017-05-12", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 13, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384734" }, { "nct_id": "NCT02154360", "title": "Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Aprepitant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2014-05", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-09-24T07:53:31.123Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154360" } ] }